Roop Lakkaraju
Analyst · Needham & Company
Thank you, Jeff, and good afternoon. Please turn to Slide 7 for our revenue by market sector. Total Benchmark revenue was $633 million in Q4, which is 11% higher sequentially and 21% higher year-over-year. Medical revenues for the fourth quarter were up 8% sequentially and 14% year-over-year which was higher than expected from continued improving demand in the cardiac and respiratory care markets. As planned, our second half medical sector revenues improved over first half 2021 levels from new programs and improving demand, which will continue in 2022. Semi-Cap revenues were up 22% sequentially and 62% year-over-year. Demand levels remain high, and our future backlog is robust for our complex precision machining and large electromechanical assembly services, which are primarily related to front-end wafer fab equipment. A&D revenues for the fourth quarter decreased 6% sequentially and 15% year-over-year from program transitions and lower demand in our commercial aerospace programs, which we -- which have yet to recover to pre-pandemic levels. Industrial revenues for the fourth quarter were up 15% sequentially and 29% year-over-year from demand improvements from oil and gas, building infrastructure and LiDAR applications. Overall, the higher value markets represented 81% of our fourth quarter revenue. In our traditional markets, computing was up 5% sequentially and 28% year-over-year from the planned ramp of high-performance computing programs that will continue throughout 2022. In the telco sector, revenues were up 15% sequentially and 16% year-over-year, primarily from demand improvement for satellite programs and new broadband ramps. Our traditional markets represented 19% of fourth quarter revenues. Our top 10 customers represented 49% of sales in the fourth quarter. Please turn to Slide 8. Our GAAP earnings per share for the quarter was $0.35. Our GAAP results included restructuring and other onetime costs totaling $4.1 million related to various restructuring activities throughout our global network, aligned to future business focus. For Q4, our non-GAAP gross margin was 9.8%. This is 50 basis points better than the midpoint of our fourth quarter guidance, driven by higher revenue, a better mix of revenue and better absorption across our global facilities. On a sequential basis, we were up 40 basis points from higher revenue, improved utilization even with supply chain inefficiencies from the current component environment. Our SG&A was $37.7 million, which was up 10% sequentially due primarily to higher variable compensation. Non-GAAP operating margin was 3.8%, which included 70 basis points of stock-based compensation. In Q4 2021, our non-GAAP effective tax rate was 22.2% because of the mix of profits between the U.S. and foreign jurisdictions. Non-GAAP EPS was $0.48 for the quarter, which is $0.07 higher than the midpoint of our Q4 guidance and $0.09 sequential improvement based on higher revenue and gross margin. Non-GAAP ROIC was 8.6%, an 80 basis point increase sequentially and a 240 basis point improvement year-over-year based on the strength of the year-over-year profit expansion. Please turn to Slide 9 for our revenue by market sector for the full year 2021 versus 2020 comparison. Total Benchmark revenue for 2021 was $2.26 billion, an increase of $200 million from revenue growth in Semi-Cap, Industrial, Computing and telco sectors. We were pleased to see growth in both the higher value and traditional market sectors. For the full year, higher-value markets were up 9% from Semi-Cap and Industrials, which increased 49% and 15%, respectively, year-over-year. Semi-Cap strength was led by increased demand across our customer base and the front-end semiconductor capital equipment space, where we provide differentiated engineering design, electronics manufacturing and precision machining services. Industrial revenues were up 15% year-over-year, primarily from continued demand improvements from oil and gas, building infrastructure and commercial transportation programs. Overall, the A&D sector declined by 10% from 2020 revenues. Higher demand levels from existing and new defense programs did not offset the persistent weakness in commercial aerospace. Overall Medical revenues decreased 7% year-over-year from the slower ramp in new medical programs, the impact of supply constraints, which limited revenue growth and lower demand for elective surgery products in the first half of 2021. While demand improved in the second half, component availability continued to limit our ability to fulfill all demand from our medical customers. Revenues in the traditional markets were up 12% from 2020. Computing was up 16% year-over-year from the planned ramp and execution of high-performance computing programs that will continue throughout 2022. Telco sector revenues were up 8% year-over-year, primarily from new program ramps and continued strength in broadband programs. Overall, the higher value markets represented 81% and traditional markets represented 19% of both our 2021 and 2020 revenue, which is consistent with our desired portfolio target of 80% higher value and 20% traditional revenues. Our top 10 customers represented 47% of sales for the full year 2021. We had 1 customer, Applied Materials, that was greater than 10% of revenue for the full year. If you will, please turn to Slide 10. Our GAAP earnings per share for fiscal year 2021 was $0.99. Our GAAP results included restructuring and other onetime costs totaling approximately $9.8 million, primarily related to site consolidation efforts, reduction in force activities and other restructuring type activities around our network. Our 2021 non-GAAP gross margin was 9.1%, a 70 basis point sequential increase. This exceeded our goal of 9% gross margin for the full year of 2021. Our non-GAAP SG&A for 2021 was $136.7 million, an increase of $14.5 million from 2020. The increase is primarily due to higher variable compensation, Medical expenses and continued IT infrastructure investments. Non-GAAP operating margin for the year was 3%, an increase from 2.5% in 2020 from higher revenue and improved gross margins from ongoing operational efficiencies. In 2021, our non-GAAP effective tax rate was 20.9%. Non-GAAP EPS in 2021 was $1.35 and non-GAAP ROIC was 8.6%. Both metrics improved substantially over 2020 levels as non-GAAP EPS grew 42% and non-GAAP ROIC grew 240 basis points. Please turn to Slide 11 to review our cash conversion cycle performance. Cash conversion cycle days were 69 in the fourth quarter compared to 71 days in Q3. Turning to Slide 12 for an update on liquidity and capital resources. During the fourth quarter, we continued to invest in inventory to support our customers. We used $1 million of cash in operations and invested $10 million in CapEx, which resulted in free cash flow usage of $11 million for the quarter. Our cash balance was $272 million at December 31, with $77 million available in the U.S. Our cash balances decreased $19 million sequentially. The decrease in cash is primarily investment in inventory to support revenue growth. As of December 31, we had $131 million outstanding on our term loan, zero outstanding borrowings against our revolver and our cash net of debt is a positive $141 million. Our strong cash balances and available liquidity continue to allow us to support our growing revenue and customer demand profile. Turning to Slide 13 to review our capital allocation activity. In 2021, we invested $42 million in capital expenditures. We had additional authorized expenditures in '21 beyond the $42 million spent, which we'll roll into this year. As such, we expect our CapEx spending in 2022 to be between $50 million and $60 million. For the full year, we expect operating cash flow to be between $40 million and $60 million as we continue to focus on cash generation while appropriately investing in inventory to support our revenue growth. In Q4, we paid cash dividends of $5.8 million and $23 million for the full year of 2021. Since 2018, we have paid cash dividends of $90 million. We did not repurchase any outstanding shares in the fourth quarter. The total share repurchases in 2021 was $40.2 million, which represented approximately 1.4 million shares or a reduction of approximately 4% of shares outstanding since the beginning of fiscal year. As of December 31, 2021, we had approximately $164 million remaining in our existing share repurchase authorization. At a minimum, we'll continue to repurchase shares to offset our annual equity dilution. Beyond that, we will evaluate share repurchases opportunistically while considering market conditions. Since 2018, we have invested approximately $200 million in our business through capital investments and returned almost $500 million of cash to shareholders through buybacks and dividends. The Benchmark balance sheet remains strong, and we expect our ability to invest in our operations and return capital to shareholders based on the strong momentum we have in our business. Please turn to Slide 14 for a review of our first quarter 2022 guidance. We expect revenue to range from $565 million to $605 million, which at the midpoint represents a 17% year-over-year improvement. For the first quarter, we expect the medical sector to grow based on increasing demand and new program ramps. We expect Semi-Cap revenue and industrial revenues to remain strong and at revenue levels consistent with Q4. A&D revenues will be down sequentially from lower volume demand Computing and telco will also be down sequentially from some near-term impacts from the timing of material availability, which will improve through the year. As Jeff mentioned earlier, the demand environment remains strong. And in each sector, demand outpaces supply. Similar to previous quarters, we have over $100 million of unfulfilled demand that continues to move into future quarters of 2022. We expect that our gross margins will be between 9% to 9.3% for Q1 and SG&A will range between $34 million and $36 million. Implied in our guidance is a 3% to 3.3% non-GAAP operating margin range for modeling purposes. The guidance provided does exclude the impact of amortization of intangible assets and estimated restructuring and other costs. We expect to incur restructuring and other nonrecurring costs in Q1 of approximately $3 million to $3.5 million. Our non-GAAP diluted earnings per share is expected to be in the range of $0.32 to $0.38 or at midpoint of $0.35. Other expenses net is expected to be $2.9 million, which is primarily interest expense related to our outstanding debt. We expect that for Q1, our non-GAAP effective tax rate will be between 19% to 21% because of the distribution of income around our global network. The expected weighted average shares for Q1 2022 are approximately 35.5 million. In summary, our guidance takes into consideration all known constraints for the quarter and assumes no further significant interruptions to our supply base, operations or customers. Guidance also assumes no material changes to end market conditions in our operations due to COVID. And with that, I'll turn the call back over to you, Jeff.